A Phase 3 Study With P2B001 in Subjects With Early Parkinson's
Public ClinicalTrials.gov record NCT03329508. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
A Phase 3, Twelve-week Study to Determine the Efficacy, Safety and Tolerability of P2B001 Once Daily Compared to Its Individual Components in Subjects With Early Parkinson's Disease and to a Calibration Arm of Pramipexole ER.
Study identification
- NCT ID
- NCT03329508
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 3
- Lead sponsor
- Pharma Two B Ltd.
- Industry
- Enrollment
- 544 participants
Conditions and interventions
Conditions
Interventions
- Marketed Pramipexole ER Drug
- P2B001 0.6/0.75 mg Drug
- Pramipexole 0.6 mg Drug
- Rasagiline 0.75 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 35 Years to 80 Years
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Jan 18, 2018
- Primary completion
- Aug 22, 2021
- Completion
- Oct 30, 2021
- Last update posted
- Mar 20, 2023
2018 – 2021
United States locations
- U.S. sites
- 45
- U.S. states
- 27
- U.S. cities
- 42
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| P2B001/003 Site Scottsdale | Scottsdale | Arizona | 85258 | — |
| P2B001/003 study site Scottsdale | Scottsdale | Arizona | 85259 | — |
| P2B001/003 Study site little Rock | Little Rock | Arkansas | 72205 | — |
| P2B001 site Los Angeles | Los Angeles | California | 90033 | — |
| P2B001 Study site Englewood, | Englewood | Colorado | 80113 | — |
| P2B001 Study Vernon | Vernon | Connecticut | 06066 | — |
| P2B001/003 site Boca Raton | Boca Raton | Florida | 33431 | — |
| P2B001/003 Site Boca Raton | Boca Raton | Florida | 33486 | — |
| P2B001/003 study site Jacksonville | Jacksonville | Florida | 32209 | — |
| P2B001/003 site Miami | Miami | Florida | 33136 | — |
| P2B001/003 Site Port Charlotte | Port Charlotte | Florida | 33980 | — |
| P2B001/003 Site Sarasota | Sarasota | Florida | 34243 | — |
| P2B001/003 Site Tampa | Tampa | Florida | 33613 | — |
| P2B001/003 Site Augusta | Augusta | Georgia | 30912 | — |
| P2B001/003 study site Honolulu | Honolulu | Hawaii | 96819 | — |
| P2B001/003 site Chicago | Chicago | Illinois | 60612 | — |
| P2B001/003 Site Winfield | Winfield | Illinois | 60190 | — |
| P2B001/003 site Kansas City | Kansas City | Kansas | 66160 | — |
| P2B001/003 Site Lexington | Lexington | Kentucky | 40536 | — |
| P2B001/003 study site Boston | Boston | Massachusetts | 02118 | — |
| P2B001/003 Site East Lansing | East Lansing | Michigan | 48824 | — |
| P2B001/003 study site west Bloomfield | West Bloomfield | Michigan | 48322 | — |
| P2B001/003 Site Golden Valley | Golden Valley | Minnesota | 55427 | — |
| P2B001/003 site St. Louis | St Louis | Missouri | 63110 | — |
| P2B001/003 study site New Hampshire | Lebanon | New Hampshire | 03756 | — |
| P2B001/003 Study site Camden | Camden | New Jersey | 08103 | — |
| P2B001 Study site Edison | Edison | New Jersey | 08820 | — |
| P2B001/003 Study site Albuquerque | Albuquerque | New Mexico | 87108 | — |
| P2B001/003 Study site Brooklyn | Brooklyn | New York | 11203 | — |
| P2B001/003 Site Commack | Commack | New York | 11725 | — |
| P2B001/003 New York | New York | New York | 10029 | — |
| P2B001 Study site Syracuse | Syracuse | New York | 13210 | — |
| P2B001/003 Study site Williamsville | Williamsville | New York | 14221 | — |
| P2B001/003 Site Asheville | Asheville | North Carolina | 28806 | — |
| P2B001 study site Cincinnati | Cincinnati | Ohio | 45219 | — |
| P2B001/003 Site Toledo | Toledo | Ohio | 43614 | — |
| P2B001/003 Study site Hershey | Hershey | Pennsylvania | 17033 | — |
| P2B001/003 Greenville | Greenville | South Carolina | 29615 | — |
| P2B0011/003 Study Veracity Neuroscience | Memphis | Tennessee | 38157 | — |
| p2B001/003 Study site Memphis | Memphis | Tennessee | 38163 | — |
| P2B001/003 Study site Nashville | Nashville | Tennessee | 37232 | — |
| P2B001/003 Site Dallas | Dallas | Texas | 75390 | — |
| P2B001/003 Study site Alexandria | Alexandria | Virginia | 22311 | — |
| P2B001/003 | Falls Church | Virginia | 22042 | — |
| P2B001/003 Site Kirkland | Kirkland | Washington | 98034 | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Non-U.S. locations
This page focuses on the U.S. directory. The official record also lists 27 non-U.S. sites.
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT03329508, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Mar 20, 2023 · Synced May 6, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT03329508 live on ClinicalTrials.gov.